Opposite movement of Infosys, Sun Pharma stocks to surprise tech, pharma fund investors
Infosys has a weight varying between 27% and 33% in technology funds. Sun Pharma, on the other hand, has weights of 15% to 25% in pharma funds.'

Infosys moved up 11.05% to end atRs 1,112.65 as it posted a sequential revenue growth of 4.5%, much above the street’s expectations, its highest quarterly revenue growth in nearly four years. Sun Pharma dived 15%, after the company issued an unexpected guidance fora disappointment in revenues. These led to the CNXIT index endingup3.45%, and CNX Pharmaindex losing 6.99% on Tuesday.
An upmove of 11% in Infosys could mean technology funds’ net asset values ( NAV) would move up by about 3.3%. Pharma funds could see their NAVs dip 3-3.5% due to the fall in the price of Sun Pharma alone in a single trading session. Pharma funds have been the best performers among sectoral funds over the last one year. As per Value Research, this category has given a return of 52.11% in the last one year, while technology funds have returned 17.67% in the same period.
Wealth managers said sectoral funds are riskier compared to other equity mutual funds as there is no restriction on the percentage of investment in a single stock. Inmany sectoral funds, the top three holdings constitute half of the portfolio.
"Since sector fundsrunconcentrated portfolios, if one or two stocks are beaten down they can hurt the portfolio significantly. Compared to this, diversified equity mutual funds that invest across sectors need to cap exposure to a single stock at 10% and henceanyimpactof astockprice fall would be limited," says Vidya Bala, head of research, Fundsindia.Com.
Download ET Markets APP